Primary Site >> Biliary tract Cancer
Gene >> KRAS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: [Detection of ras gene mutations of primary hepatic malignant tumors by polymerase chain reaction and direct sequencing method]. PMID: 2167400 |
Ref: The point mutation of c-Ki-ras at codon 12 in carcinoma of the pancreatic head region and in intraductal mucin-hypersecreting neoplasm of the pancreas. PMID: 8283077 Ref: Neoplasia of the ampulla of Vater. Ki-ras and p53 mutations. PMID: 8475992 Ref: [Detection of point mutation of K-ras gene codon 12 in biliary tract and ampullary carcinoma by modified two-step polymerase chain reaction]. PMID: 8492470 |
Ref: High rates of Ki-ras point mutation in both intra- and extra-hepatic cholangiocarcinomas. PMID: 7830335 Ref: Point mutation of K-ras gene codon 12 in biliary tract tumors. PMID: 7926462 Ref: ras-family gene mutations in neoplasia of the ampulla of Vater. PMID: 7927901 Ref: Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. PMID: 8012983 Ref: Diagnosis of pancreatic adenocarcinoma by polymerase chain reaction from pancreatic secretions. PMID: 8054276 |
Ref: Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. PMID: 7557145 Ref: Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. PMID: 7796400 Ref: Analysis of K-ras gene mutations in periampullary cancers, gallbladder cancers and cholangiocarcinomas from paraffin-embedded tissue sections. PMID: 8541732 Ref: Detection of point mutations in K-ras gene at codon 12 in bile from percutaneous transhepatic choledochal drainage tubes for diagnosis of biliary strictures. PMID: 8708392 Ref: Detection of c-Ki-ras mutations in bile samples from patients with pancreatic and biliary cancers. PMID: 16696030 |
Ref: K-ras point mutations in cancerous and noncancerous biliary epithelium in patients with pancreaticobiliary maljunction. PMID: 8608574 Ref: Point mutations of the c-Ki-ras gene in carcinoma and atypical epithelium associated with congenital biliary dilation. PMID: 8651173 Ref: Clinical significance of K-ras oncogene activation in ampullary neoplasms. PMID: 8763258 Ref: Detection of ras oncogene point mutations and simultaneous proliferative fraction estimation in gallbladder cancer. PMID: 8857639 |
Ref: K-ras gene mutations in intrahepatic bile duct tumors of Syrian golden hamsters. PMID: 9354164 Ref: Analysis of K-ras gene mutations in human pancreatic cancer cell lines and in bile samples from patients with pancreatic and biliary cancers. PMID: 21590256 |
Ref: Usefulness of K-ras gene mutation at codon 12 in bile for diagnosing biliary strictures. PMID: 9538122 Ref: The incidence of K-ras codon 12 mutations in cholangiocarcinoma detected by polymerase chain reaction technique. PMID: 9623030 Ref: Relative contribution of Ki-ras gene analysis and brush cytology during ERCP for the diagnosis of biliary and pancreatic diseases. PMID: 9647372 Ref: K-ras oncogene and p53 gene mutations in cholangiocarcinoma from Thai patients. PMID: 9740272 Ref: Analysis of K-ras gene mutations in rare pancreatic and ampullary tumours. PMID: 9895049 |
Ref: K-ras point mutations in the supernatants of pancreatic juice and bile are reliable for diagnosis of pancreas and biliary tract carcinomas complementary to cytologic examination. PMID: 10189896 Ref: Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. PMID: 10212000 Ref: Gene mutations of K-ras in gallbladder mucosae and gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. PMID: 10364037 Ref: Gallbladder carcinoma. PMID: 10436804 Ref: Losses of heterozygosity on chromosomes 17p and 9p/18q may play important roles in early and advanced phases of gallbladder carcinogenesis. PMID: 10480335 Ref: Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. PMID: 10526058 Ref: Analysis of genetic changes in intrahepatic cholangiocarcinoma induced by thorotrast. PMID: 10564951 |
Ref: Chronic inflammatory bowel disease and cancer. PMID: 10690586 Ref: Relation between K-ras codon 12 mutation and p53 protein overexpression in gallbladder cancer and biliary ductal epithelia in patients with pancreaticobiliary maljunction. PMID: 10982614 Ref: K-ras oncogene mutation in cancer and precancerous lesions of the gallbladder. PMID: 11135265 Ref: p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. PMID: 11180865 |
Ref: Allelotype analysis of gallbladder carcinoma associated with anomalous junction of pancreaticobiliary duct. PMID: 11311485 Ref: Genetic alterations in gallbladder adenoma, dysplasia and carcinoma. PMID: 11410326 |
Ref: Clinical and genetic analysis of noncancerous and cancerous biliary epithelium in patients with pancreaticobiliary maljunction. PMID: 11898040 Ref: Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. PMID: 12063950 Ref: K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. PMID: 12374683 Ref: Biliary papillomatosis arising in a congenital choledochal cyst: report of a case. PMID: 12444445 |
Ref: Mutation analysis of K-ras and beta-catenin genes related to O6-methylguanin-DNA methyltransferase and mismatch repair protein status in human gallbladder carcinoma. PMID: 12469220 Ref: Role of the DPC4 tumor suppressor gene in adenocarcinoma of the ampulla of Vater: analysis of 140 cases. PMID: 12640108 Ref: Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. PMID: 12692057 Ref: Immunohistochemical and genetic analysis of non-small cell and small cell gallbladder carcinoma and their precursor lesions. PMID: 12692194 Ref: DPC-4 (Smad-4) and K-ras gene mutations in biliary tract epithelium in children with anomalous pancreaticobiliary ductal union. PMID: 12720172 Ref: Molecular and immunohistochemical analysis of intraductal papillary neoplasms of the biliary tract. PMID: 14562286 |
Ref: Mutational spectrum of K-ras oncogene among Indian patients with gallbladder cancer. PMID: 15242496 Ref: [K-ras gene mutation in gallbladder carcinoma]. PMID: 15478297 |
Ref: Histologic and genetic analysis of the gallbladder in patients with occult pancreatobiliary reflux. PMID: 15702232 Ref: [Frequency of K-ras mutation in biliary and pancreatic tumors]. PMID: 16446870 |
Ref: K-ras, p53 mutations, and microsatellite instability (MSI) in gallbladder cancer. PMID: 16724348 Ref: Double cancer of gall bladder and bile duct not associated with anomalous junction of the pancreaticobiliary duct system. PMID: 16908513 |
Ref: Dual blockade of the Hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells. PMID: 17294242 Ref: Diagnosis and surgical management of gallbladder cancer: a review. PMID: 17468929 |
Ref: Mutations of KRAS and TP53 in a minor proportion of Opisthorchis viverrini-associated cholangiocarcinomas in a hamster model. PMID: 18439086 Ref: Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma. PMID: 18677542 Ref: Biomarkers in carcinoma of the gallbladder. PMID: 23495740 |
Ref: p53 gene mutation and p53 protein overexpression in a patient with simultaneous double cancer of the gallbladder and bile duct associated with pancreaticobiliary maljunction. PMID: 19183832 Ref: Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. PMID: 19319137 Ref: Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas. PMID: 19440799 Ref: Ultrasensitive detection of KRAS2 mutations in bile and serum from patients with biliary tract carcinoma using LigAmp technology. PMID: 19815696 |
Ref: Identification of transforming activity of free fatty acid receptor 2 by retroviral expression screening. PMID: 19780758 Ref: Long-term culture following ES-like gene-induced reprogramming elicits an aggressive phenotype in mutated cholangiocellular carcinoma cells. PMID: 20381452 Ref: Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. PMID: 20565817 Ref: [Genetic alterations in preneoplastic and neoplastic injuries of the gallbladder]. PMID: 20668816 Ref: DNA mutational differences in cytological specimens from pancreatic cancer and cholangiocarcinoma. PMID: 20720444 Ref: Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography. PMID: 20864634 |
Ref: KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients. PMID: 21051183 Ref: Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. PMID: 21303542 Ref: Mutations in the RAS/RAF/MAP kinase pathway commonly occur in gallbladder adenomas but are uncommon in gallbladder adenocarcinomas. PMID: 21307665 Ref: A novel polymorphism in codon 25 of the KRAS gene associated with gallbladder carcinoma patients of the eastern part of India. PMID: 21375404 Ref: Genetics of hepatobiliary carcinogenesis. PMID: 21538283 Ref: Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers. PMID: 21611090 |
Ref: Intraductal tubulopapillary neoplasm of the bile duct: potential origin from peribiliary cysts. PMID: 21813159 Ref: Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. PMID: 22178589 Ref: Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. PMID: 22180306 Ref: Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. PMID: 22210086 Ref: Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. PMID: 22266220 Ref: Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer. PMID: 22367707 Ref: Genetic profiling of intrahepatic cholangiocarcinoma. PMID: 22395571 Ref: Exome sequencing of liver fluke-associated cholangiocarcinoma. PMID: 22561520 Ref: Cancer of the ampulla of Vater: analysis of the whole genome sequence exposes a potential therapeutic vulnerability. PMID: 22762308 Ref: Establishment and characterization of a new human gallbladder carcinoma cell line. PMID: 22843894 Ref: Molecular analysis of centrifugation supernatant fluid from pancreaticobiliary duct samples can improve cancer detection. PMID: 22846349 |
Ref: Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma. PMID: 22810956 Ref: Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. PMID: 23295441 Ref: Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. PMID: 23318457 Ref: KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas. PMID: 23335286 Ref: Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. PMID: 23391413 Ref: Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. PMID: 23391555 Ref: PTEN loss and KRAS activation cooperate in murine biliary tract malignancies. PMID: 23483557 Ref: Adjuvant gemcitabine therapy improves survival in a locally induced, R0-resectable model of metastatic intrahepatic cholangiocarcinoma. PMID: 23686746 Ref: Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study. PMID: 24007821 Ref: The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome. PMID: 24139215 Ref: A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma. PMID: 24146220 |
Ref: Curative resection of hilar cholangiocarcinoma in a 25-year-old woman: report of a case. PMID: 23580078 Ref: Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways. PMID: 23828315 Ref: Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. PMID: 24122810 Ref: High throughput molecular profiling reveals differential mutation patterns in intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases. PMID: 24186137 Ref: Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels. PMID: 24186143 Ref: Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan. PMID: 24372748 Ref: Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features. PMID: 24406866 Ref: Molecular characterization of gallbladder cancer using somatic mutation profiling. PMID: 24508317 Ref: Potential biomarkers for sensitivity of gallbladder cancer cells to gemcitabine. PMID: 24551272 Ref: New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. PMID: 24563076 Ref: Gallbladder cancers: associated conditions, histological types, prognosis, and prevention. PMID: 24614695 Ref: Mutation profiling in gallbladder cancer in Indian population. PMID: 24739824 Ref: Epstein-Barr virus-associated lymphoepithelioma-like cholangiocarcinoma: a rare variant of intrahepatic cholangiocarcinoma with favourable outcome. PMID: 24804938 Ref: Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. PMID: 24889489 Ref: Molecular mechanism of cholangiocarcinoma carcinogenesis. PMID: 24895231 Ref: Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. PMID: 24960403 Ref: Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. PMID: 24997986 Ref: High frequency of TP53 but not K-ras gene mutations in Bolivian patients with gallbladder cancer. PMID: 25041017 Ref: Mutant IDH inhibits HNF-4alpha to block hepatocyte differentiation and promote biliary cancer. PMID: 25043045 Ref: Different carcinogenic process in cholangiocarcinoma cases epidemically developing among workers of a printing company in Japan. PMID: 25197345 Ref: Mutational landscape of intrahepatic cholangiocarcinoma. PMID: 25526346 Ref: Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PMID: 25536104 |
Ref: Molecular diagnosis of intrahepatic cholangiocarcinoma. PMID: 25267595 Ref: Autophagy may occur at an early stage of cholangiocarcinogenesis via biliary intraepithelial neoplasia. PMID: 25466963 Ref: Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. PMID: 25608663 Ref: A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. PMID: 25632066 Ref: Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity. PMID: 25636086 Ref: Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer. PMID: 25749176 Ref: Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways. PMID: 25966424 Ref: Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2). PMID: 25975284 Ref: Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases. PMID: 26111977 Ref: Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing. PMID: 26189129 Ref: Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. PMID: 26189560 Ref: Cholangiocarcinoma: from molecular biology to treatment. PMID: 26427701 Ref: High DBC1 (CCAR2) expression in gallbladder carcinoma is associated with favorable clinicopathological factors. PMID: 26617872 |
Ref: Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma. PMID: 26405193 Ref: Intraductal tubulopapillary neoplasm of the bile duct: A case report and review of the published work. PMID: 26459784 Ref: Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. PMID: 26500333 Ref: Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study). PMID: 26540314 Ref: Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients. PMID: 26717940 Ref: Cholangiocarcinoma with intraductal tubular growth pattern versus intraductal papillary growth pattern. PMID: 26769137 Ref: Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma. PMID: 26806338 Ref: Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation. PMID: 26868125 Ref: Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. PMID: 26956004 Ref: Two classes of intrahepatic cholangiocarcinoma defined by relative abundance of mutations and copy number alterations. PMID: 27009864 Ref: A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion. PMID: 27032374 Ref: The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. PMID: 27102149 Ref: Long non-coding RNA Malat1 promotes gallbladder cancer development by acting as a molecular sponge to regulate miR-206. PMID: 27191262 Ref: Distinct Clinicopathologic and Genetic Features of 2 Histologic Subtypes of Intrahepatic Cholangiocarcinoma. PMID: 27259014 Ref: Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing. PMID: 27267833 Ref: Loss of ARID1A Expression Presents a Novel Pathway of Carcinogenesis in Biliary Carcinomas. PMID: 27334809 Ref: TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer. PMID: 27335026 Ref: Comparative clinicopathological study of biliary intraductal papillary neoplasms and papillary cholangiocarcinomas. PMID: 27410028 Ref: APC promoter is frequently methylated in pancreatic juice of patients with pancreatic carcinomas or periampullary tumors. PMID: 27602165 Ref: A let-7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population. PMID: 27620744 Ref: Biliary cancer: Utility of next-generation sequencing for clinical management. PMID: 27622582 Ref: Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice. PMID: 27658789 Ref: Molecular characteristics of biliary tract cancer. PMID: 27823638 Ref: Gallbladder cancer: South American experience. PMID: 27829280 Ref: KRAS Mutation as a Potential Prognostic Biomarker of Biliary Tract Cancers. PMID: 28008299 |
Ref: Mutation analysis and copy number changes of KRAS and BRAF genes in Taiwanese cases of biliary tract cholangiocarcinoma. PMID: 27745798 Ref: KRAS mutation in biliary tract cholangiocarcinoma. PMID: 28007466 Ref: Corrigendum: A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion. PMID: 28045050 Ref: Concurrent MET copy number gain and KRAS mutation is a poor prognostic factor in pancreatobiliary subtype ampullary cancers. PMID: 28214200 Ref: Genomic and proteomic characterization of ARID1A chromatin remodeller in ampullary tumors. PMID: 28401006 Ref: Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands. PMID: 28439013 Ref: L1 Cell Adhesion Molecule Promotes Migration and Invasion via JNK Activation in Extrahepatic Cholangiocarcinoma Cells with Activating KRAS Mutation. PMID: 28535665 Ref: Kupffer Cell-Derived Tnf Triggers Cholangiocellular Tumorigenesis through JNK due to Chronic Mitochondrial Dysfunction and ROS. PMID: 28609656 Ref: Genetic alterations in Japanese extrahepatic biliary tract cancer. PMID: 28693246 Ref: Adenosquamous gallbladder carcinoma: Multigene hotspot mutational profiling reveals a monoclonal origin of the two components. PMID: 28698100 Ref: Mutational frequency of KRAS, NRAS, IDH2, PIK3CA, and EGFR in North Indian gallbladder cancer patients. PMID: 28900470 Ref: Ampullary cancer of intestinal origin and duodenal cancer - A logical clinical and therapeutic subgroup in periampullary cancer. PMID: 29085567 Ref: Establishment of cholangiocarcinoma cell lines from patients in the endemic area of liver fluke infection in Thailand. PMID: 29110582 Ref: Kras(G12D) upregulates Notch signaling to induce gallbladder tumorigenesis in mice. PMID: 29142904 Ref: Utility of KRAS mutational analysis in the preoperative diagnosis of synchronous pancreatic cancer and intrahepatic cholangiocarcinoma: A case report. PMID: 29390348 |
Ref: Targeting cholangiocarcinoma. PMID: 28844952 Ref: Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. PMID: 29278425 Ref: MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations. PMID: 29309301 Ref: Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer. PMID: 29334603 Ref: Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer. PMID: 29348486 Ref: Primary Liver Cancers, Part 2: Progression Pathways and Carcinogenesis. PMID: 29353494 Ref: Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. PMID: 29360550 Ref: Establishment and analysis of a novel mouse line carrying a conditional knockin allele of a cancer-specific FBXW7 mutation. PMID: 29386660 Ref: PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study. PMID: 29413685 Ref: Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers. PMID: 29416916 Ref: Combination of Kras activation and PTEN deletion contributes to murine hepatopancreatic ductal malignancy. PMID: 29452147 Ref: Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study. PMID: 29527009 Ref: Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma. PMID: 29551704 Ref: Molecular genomic landscapes of hepatobiliary cancer. PMID: 29573058 Ref: The Novel Selective Pan-TRK Inhibitor ONO-7579 Exhibits Antitumor Efficacy Against Human Gallbladder Cancer In Vitro. PMID: 29599313 Ref: Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by (18)F-FDG-PET is associated with the KRAS mutation status and prognosis. PMID: 29642912 Ref: Interleukin-33 overexpression reflects less aggressive tumour features in large-duct type cholangiocarcinomas. PMID: 29675965 Ref: Mucinous intrahepatic cholangiocarcinoma: a distinct variant. PMID: 29698701 Ref: Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer. PMID: 29785570 Ref: Ampullary carcinoma-A genetic perspective. PMID: 29807574 Ref: Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. PMID: 29848569 Ref: Kras and Tp53 Mutations Cause Cholangiocyte- and Hepatocyte-Derived Cholangiocarcinoma. PMID: 29871934 Ref: ACGH detects distinct genomic alterations of primary intrahepatic cholangiocarcinomas and matched lymph node metastases and identifies a poor prognosis subclass. PMID: 30006612 Ref: Pancreatic and bile duct cancer circulating tumor cells (CTC) form immune-resistant multi-cell type clusters in the portal venous circulation. PMID: 30067440 Ref: Emergence of Intrahepatic Cholangiocarcinoma: How High-Throughput Technologies Expedite the Solutions for a Rare Cancer Type. PMID: 30158952 Ref: ERBB2 and KRAS Alterations Mediate Response to EGFR Inhibitors in Early Stage Gallbladder Cancer. PMID: 30304546 Ref: EVI1 expression is associated with aggressive behavior in intrahepatic cholangiocarcinoma. PMID: 30349952 |